Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Trial Identifier: D8330C00001
Sponsor: AstraZeneca
NCTID:: NCT04630067
Start Date: November 2020
Primary Completion Date: September 2022
Study Completion Date: September 2022
Condition: Congestive Heart Failure

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish (US) Translation
Japanese Translation

Trial Locations

Country Location
US, AR Little Rock, AR, US, 72204
US, CA Glendale, CA, US, 91206
US, FL Daytona Beach, FL, US, 32117
US, FL Doral, FL, US, 33166
US, FL Hallandale Beach, FL, US, 33009
US, FL Jacksonville, FL, US, 32216
US, IN Richmond, IN, US, 47374
US, KY Owensboro, KY, US, 42303
US, MD Brooklyn, MD, US, 21225
US, MI Detroit, MI, US, 48202
US, MO Saint Louis, MO, US, 63136
US, TX Houston, TX, US, 77030